Skip to main content
SpringerLink
Log in

Regional Chemotherapy for Recurrent Platin Refractory Ovarian Cancer

  • Chapter
  • First Online:
Induction Chemotherapy

Abstract

In ovarian cancers that relapse within six months and are platin-refractory, treatment options are very limited and the disease is considered non curable. Dose-dense and high dose drug exposure caused accentuated and intolerable toxicity without considerable impact on quality of life. Isolated abdominal perfusion taking advantage from increased cytotoxicity of some drugs under hypoxic conditions can break through acquired chemoresistance of ovarian cancer. In a phase II study where 63 patients with pretreated recurrent chemoresistant tumors served as their own control, a 64 % clinical response rate (25 % CR, 39 % PR) and 43 % complete resolution of ascites was achieved. Median PFS and OS were 8 months and 14 months respectively. 8 Patients have been surviving between 6 and 18 years. Out of 4 patients surviving between 10 and 18 years, 3 initially had G3 tumors. Subsequent systemic chemofiltration after therapies markedly reduces toxicity and maintains good quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–11.

    Article  PubMed  CAS  Google Scholar 

  2. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ­ova­rian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–93.

    PubMed  CAS  Google Scholar 

  3. Ozols RF. Treatment of recurrent ovarian cancer: increasing options – “recurrent” results. J Clin Oncol. 1997;15:2177–80.

    PubMed  CAS  Google Scholar 

  4. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2005;23:1859–66.

    Article  PubMed  CAS  Google Scholar 

  5. Gore M, Mainwaring P, A’Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol. 1998;16:2426–34.

    PubMed  CAS  Google Scholar 

  6. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520–8.

    PubMed  CAS  Google Scholar 

  7. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987;5:756–67.

    PubMed  CAS  Google Scholar 

  8. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995;13:1589–99.

    PubMed  CAS  Google Scholar 

  9. Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003;21:2843–8.

    Article  PubMed  CAS  Google Scholar 

  10. Thigpen JT. Dose-intensity in ovarian carcinoma: hold, enough? J Clin Oncol. 1997;15:1291–3.

    PubMed  CAS  Google Scholar 

  11. Grenman S, Wiklund T, Jalkanen J, et al. A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian (FINOVA) study. Eur J Cancer. 2006;42:2196–9.

    Article  PubMed  CAS  Google Scholar 

  12. Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimming R, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007;25:4187–93.

    Article  PubMed  Google Scholar 

  13. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to Carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol. 2006;24:1127–35.

    Article  PubMed  Google Scholar 

  14. Fung MF, Johnston ME, Eisenhauer EA, Elit L, HIrte HW, Rosen B, et al. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum – a systematic review of the evidence from randomized trials. Eur J Gynaec Oncol. 2002;23:104–10.

    Google Scholar 

  15. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m²) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009;114:195–8.

    Article  PubMed  CAS  Google Scholar 

  16. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460–5.

    Article  PubMed  CAS  Google Scholar 

  17. Huang Lan, Cronin Kathleen A, Johnson Karen A, Mariotto Angela B, Feuer Eric J. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer. 2010;112:2289–300.

    Article  Google Scholar 

  18. Aigner KR, Gailhofer S, et al. Hypoxic abdominal perfusion for recurrent platin refractory ovarian cancer. Cancer Ther. 2008;6:213–20.

    CAS  Google Scholar 

  19. Creech O, Krementz ET, Ryan RF, Winbald JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–32.

    Article  PubMed  Google Scholar 

  20. Kroon BBR. Regional isolated perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol. 1988;14:101–10.

    PubMed  CAS  Google Scholar 

  21. Teicher BA, Lazo JS, Sartorelli A. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 1981;41:73–81. Cancer Research 1981.

    PubMed  CAS  Google Scholar 

  22. Aigner KR, Gailhofer S. High dose MMC: aortic stopflow infusion (ASI) with versus without chemofiltration: a comparison of toxic side effects (abstract). Reg Cancer Treat. 1993;6 Suppl 1:3.

    Google Scholar 

  23. Muchmore JH, Aigner KR, Beg MH. Regional chemotherapy for advanced intraabdominal and pelvic cancer. In: Cohen AM, Winawer SJ, Friedman MA, Gunderson LL, editors. Cancer of the colon, rectum and anus. New York: McGraw Hill; 1995. p. 881–9. In Albert Cohn Colorectal Cancer.

    Google Scholar 

  24. Monk BJ, Han E, Joseph-Cowen CA, Pugmire G, Burger RA. Salvage bevacizumab-(rhuMABVEGF)-based therapy after multiple prior cytotoxics regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006;102:140–4.

    Article  PubMed  CAS  Google Scholar 

  25. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of Bevacizumab in ­persistent or recurrent epithelial ovarian cancer of primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165–71.

    Article  PubMed  CAS  Google Scholar 

  26. Cannistra SA. The ethics of early stopping rules: who is protecting whom? J Clin Oncol. 2004;22:1542–5.

    Article  PubMed  Google Scholar 

  27. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol. 2005;23:8802–11.

    Article  PubMed  Google Scholar 

  28. Stephens FO, Harker GJS, Crea P. The intra-arterial Infusion of chemotherapeutic agents as “basal” treatment of cancer: evidence of increased drug activity in regionally infused tissues. Aust NZ J Surg. 1980;50:597–602.

    Article  CAS  Google Scholar 

  29. Stephens FO. Why use regional chemotherapy? Principles and pharmacokinetics. Reg Cancer Treat. 1988;1:4–10.

    Google Scholar 

  30. Stephens FO. Induction (neo-adjuvant) chemotherapy systemic and arterial delivery techniques and their clinical applications. Aust NZ J Surg. 1995;65:699–707.

    Article  CAS  Google Scholar 

  31. Stephens FO. Induction (neo-adjuvant) chemotherapy: the place and techniques of using chemotherapy to downgrade aggressive or advanced localised cancers to make them potentially more curable by surgery and/or radiotherapy. Eur J Surg Oncol. 2001;27(7):627–88.

    Article  Google Scholar 

  32. Stone Rebecca L, Sood Anil K, Coleman Robert L. Collateral damage: toxic effects of ­targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010;11:465–75.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Medias Klinikum GmbH & Co KG, Krankenhausstrasse 14a, 84489, Burghausen, Germany

    Karl Reinhard Aigner & Sabine Gailhofer

Authors
  1. Karl Reinhard Aigner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabine Gailhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Reinhard Aigner .

Editor information

Editors and Affiliations

  1. Abt. Onkologische Chirurgie, Medias Klinikum GmbH & Co. KG, Krankenhausstr. 1, Burghausen, 84489, Germany

    Karl Reinhard Aigner

  2. Inkerman Street 16, Mosman, 2088, New South Wales, Australia

    Frederick O. Stephens

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Aigner, K.R., Gailhofer, S. (2011). Regional Chemotherapy for Recurrent Platin Refractory Ovarian Cancer. In: Aigner, K., Stephens, F. (eds) Induction Chemotherapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18173-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18173-3_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-18172-6

  • Online ISBN: 978-3-642-18173-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation